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BAYESIAN DATA AUGMENTATION DOSE FINDING
WITH CONTINUAL REASSESSMENT METHOD AND
DELAYED TOXICITY
By Suyu Liu∗, Guosheng Yin†,1 and Ying Yuan∗,2
MD Anderson Cancer Center∗ and University of Hong Kong†
A major practical impediment when implementing adaptive dose-
finding designs is that the toxicity outcome used by the decision rules
may not be observed shortly after the initiation of the treatment. To
address this issue, we propose the data augmentation continual re-
assessment method (DA-CRM) for dose finding. By naturally treating
the unobserved toxicities as missing data, we show that such missing
data are nonignorable in the sense that the missingness depends on
the unobserved outcomes. The Bayesian data augmentation approach
is used to sample both the missing data and model parameters from
their posterior full conditional distributions. We evaluate the perfor-
mance of the DA-CRM through extensive simulation studies and also
compare it with other existing methods. The results show that the
proposed design satisfactorily resolves the issues related to late-onset
toxicities and possesses desirable operating characteristics: treating
patients more safely and also selecting the maximum tolerated dose
with a higher probability. The new DA-CRM is illustrated with two
phase I cancer clinical trials.
1. Introduction. The continual reassessment method (CRM) proposed
by O’Quigley, Pepe and Fisher (1990) is an influential phase I clinical trial
design for finding the maximum tolerated dose (MTD) of a new drug. The
CRM assumes a single-parameter working dose–toxicity model and contin-
uously updates the estimates of the toxicity probabilities of the considered
doses to guide dose escalation. Under some regularity conditions, the MTD
identified by the CRM generally converges to the true MTD, even when
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the working model is misspecified [Shen and O’Quigley (1996)]. A vari-
ety of extensions of the CRM have been proposed to improve its practical
implementation and operating characteristics [Goodman, Zahurak and Pi-
antadosi (1995); Mo¨ller (1995); Heyd and Carlin (1999); Leung and Wang
(2002); O’Quigley and Paoletti (2003); Garrett-Mayer (2006); Iasonos and
O’Quigley (2011); among others]. Recently, several robust versions of the
CRM have been proposed by using the Bayesian model averaging and poste-
rior maximization [Yin and Yuan (2009) and Daimon, Zohar and O’Quigley
(2011)], so that the method is insensitive to the prior specification of the
dose–toxicity model.
In real applications, to achieve its best performance, the CRM requires
that the toxicity outcome be observed quickly such that, by the time of
the next dose assignment, the toxicity outcomes of the currently treated
patients have been completely observed. However, late-onset toxicities are
common in phase I clinical trials, especially in oncology areas. For example,
in radiotherapy trials, dose-limiting toxicities (DLTs) often occur long after
the treatment is finished [Coia, Myerson and Tepper (1995)]. Desai et al.
(2007) reported a phase I study to determine the MTD of oxaliplatin for
combination with gemcitabine and the concurrent radiation therapy in pan-
creatic cancer. In that trial, on average, a new patient arrived every two
weeks, whereas it took nine weeks to assess the toxicity outcomes of the pa-
tients after the treatment is initiated. Consequently, at the moment of dose
assignment for a newly arrived patient, the patients under treatment might
not have yet completed the full assessment period and, thus, their toxicity
outcomes might not be available for making the decision of dose assignment.
Late-onset toxicity has been becoming a more critical issue in the emerging
era of the development of novel molecularly targeted agents, because many
of these agents tend to induce late-onset toxicities. A recent review paper in
the Journal of Clinical Oncology found that among a total of 445 patients
involved in 36 trials, 57% of the grade 3 and 4 toxicities were late-onset and,
as a result, particular attention has been called upon the issue of late-onset
toxicity [Postel-Vinay et al. (2011)].
Our research is motivated by one of the collaborative projects, which in-
volves the combination of chemo- and radiation therapy. The trial aims to
determine the MTD of a chemo-treatment, while the radiation therapy is de-
livered as a simultaneous integrated boost in patients with locally advanced
esophageal cancer. The DLT is defined as CTCAE 3.0 (Common Terminol-
ogy Criteria for Adverse Events version 3.0) grade 3 or 4 esophagitis, and
the target toxicity rate is 30%. In this trial, six dose levels are investigated
and toxicity is expected to be late-onset. The accrual rate is approximately
3 patients per month, but it generally takes 3 months to fully assess toxi-
city for each patient. By the time of dose assignment for a newly enrolled
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patient, some patients who have not experienced toxicity thus far may ex-
perience toxicity later during the remaining follow-up. It is worth noting
that whether we view toxicity as late-onset or not is relative to the patient
accrual rate. If patients enter the trial at a fast rate and toxicity evaluation
cannot keep up with the speed of enrollment, this situation is considered as
late-onset toxicity. On the other hand, if the patient accrual is very slow,
for example, one patient every three months, and toxicity evaluation also re-
quires a follow-up of three months, then the trial conduct may not cause any
missing data problem. For broader applications besides this chemo-radiation
trial and to gain more insight into the missing data issue, we explore sev-
eral options to design such late-onset toxicity trials, including the CRM and
some other possibilities discussed below.
Operatively, the CRM does not require that toxicity must be immediately
observable, and the update of posterior estimates and dose assignment can
be based on the currently observed toxicity data while ignoring the missing
data. However, such observed data represent a biased sample of the pop-
ulation because patients who would experience toxicity are more likely to
be included in the sample than those who do not experience toxicity. In
other words, the observed data contain an excessively higher percentage of
toxicity than the complete data. Consequently, the estimates based on only
the observed data tend to overestimate the toxicity probabilities and lead
to overly conservative dose escalation. Alternatively, Cheung and Chappell
(2000) proposed the time-to-event CRM (TITE-CRM), in which subjects
who have not experienced toxicity thus far are weighted by their follow-
up times. Based on similar weighting methods, Braun (2006) studied both
early- and late-onset toxicities in phase I trials; Mauguen, Le Deley and
Zohar (2011) investigated the EWOC design with incomplete toxicity data;
and Wages, Conaway and O’Quigley (2013) proposed a dose-finding method
for drug-combination trials. Yuan and Yin (2011) proposed an expectation–
maximization (EM) CRM approach to handling late-onset toxicity.
In the Bayesian paradigm, we propose a data augmentation approach
to resolving the late-onset toxicity problem based upon the missing data
methodology [Little and Rubin (2002); and Daniels and Hogan (2008)]. By
treating the unobserved toxicity outcomes as missing data, we naturally
integrate the missing data technique and theory into the CRM framework.
In particular, we establish that the missing data due to late-onset toxicities
are nonignorable. We propose the Bayesian data augmentation CRM (DA-
CRM) to iteratively impute the missing data and sample from the posterior
distribution of the model parameters based on the imputed likelihood.
The remainder of the article is organized as follows. In Section 2 we briefly
review the original CRM methodology and propose the DA-CRM based on
Bayesian data augmentation to address the missing data issue caused by
late-onset toxicity. In Section 3.1 we present simulation studies to compare
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the operating characteristics of the new design with other available methods,
and in Section 3.2 we conduct a sensitivity analysis to further investigate the
properties of the DA-CRM. We illustrate the proposed DA-CRM design with
two cancer clinical trials in Section 4, and conclude with a brief discussion
in Section 5.
2. Dose-finding methods.
2.1. Continual reassessment method. In a phase I dose-finding trial, pa-
tients enter the study sequentially and are followed for a fixed period of
time (0, T ) to assess the toxicity of the drug. During this evaluation window
(0, T ), we measure a binary toxicity outcome for each subject i,
Yi =
{
1, if a drug-related toxicity is observed in (0, T ),
0, if no drug-related toxicity is observed in (0, T ).
Typically, the length of the assessment period T is chosen so that if a drug-
related toxicity occurs, it would occur within (0, T ). Depending on the nature
of the disease and the treatment agent, the assessment period T may vary
from days to months.
Suppose that a set of J doses of a new drug are under investigation, the
CRM assumes a working dose–toxicity curve, such as
pid = α
exp(a)
d , d= 1, . . . , J,
where pid is the true toxicity probability at dose level d, αd is the prespecified
probability constant, satisfying a monotonic dose–toxicity order α1 < · · ·<
αJ , and a is an unknown parameter. We continuously update this dose–
toxicity curve by re-estimating a based on the observed toxicity outcomes
in the trial.
Suppose that n patients have entered the trial, and let yi and di denote
the binary toxicity outcome and the received dose level for the ith subject,
respectively. The likelihood function based on the toxicity outcomes y =
{yi, i= 1, . . . , n} is given by
L(y|a) =
n∏
i=1
{α
exp(a)
di
}yi{1− α
exp(a)
di
}1−yi .
Assuming a prior distribution f(a) for a, for example, f(a) is a normal
distribution with mean 0 and variance σ2, a∼N(0, σ2), then the posterior
distribution of a is given by
f(a|y) =
L(y|a)f(a)∫
L(y|a)f(a)da
,(2.1)
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and the posterior means of the dose–toxicity probabilities are given by
pˆid =
∫
α
exp(a)
d f(a|y)da, d= 1, . . . , J.
Based on the updated estimates of the toxicity probabilities, the CRM as-
signs a new cohort of patients to dose level d∗ which has an estimated toxicity
probability closest to the prespecified target φ, that is,
d∗ = argmin
d∈(1,...,J)
|pˆid − φ|.
The trial continues until the exhaustion of the total sample size, and then
the dose with an estimated toxicity probability closest to φ is selected as the
MTD.
2.2. Nonignorable missing data. One of the practical limitations of the
CRM is that the DLT needs to be ascertainable quickly after the initiation
of the treatment. Figure 1 illustrates the situation where the patient inter-
arrival time τ is shorter than the assessment period T . By the time a dose is
to be assigned to a newly accrued patient (say, patient 4 at time 3τ ), some
of the patients who have entered the trial (i.e., patients 2 and 3) may have
Fig. 1. Illustration of missing toxicity outcomes under fast accrual. For each patient, the
horizontal line segment represents the follow-up, on which toxicity is indicated by a cross.
At time τ , the toxicity outcome of patient 1 is missing (i.e., Y1 is missing); at time 2τ ,
the toxicity outcome of patient 2 is missing (i.e., Y1 = 1, but Y2 is missing); and at time
3τ , the toxicity outcomes of both patients 2 and 3 are missing (i.e., Y1 = 1, but Y2 and Y3
are missing).
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been partially followed and their toxicity outcomes are still not available.
More precisely, for the ith subject, let ti denote the time to toxicity. For
subjects who do not experience toxicity during the trial, we set ti =∞. At
the moment of decision making for dose assignment, let ui (0≤ ui ≤ T ) de-
note the actual follow-up time for subject i, and let Mi(ui) be the missing
data indicator for Yi. Then it follows that
Mi(ui) =
{
1, if ti > ui and ui < T ,
0, if ti ≤ ui or ui = T.
(2.2)
That is, the toxicity outcome is missing with Mi(ui) = 1 for patients who
have not yet experienced toxicity (ti >ui) and have not been fully followed
up to T (ui < T ); and the toxicity outcome is observed with Mi(ui) = 0
when patients either have experienced toxicity (ti ≤ ui) or have completed
the entire follow-up (ui = T ) without experiencing toxicity. For notational
simplicity, we suppress ui and take Mi ≡Mi(ui). Due to patients’ staggered
entry, it is reasonable to assume that ui is independent of ti, that is, the
time of dose assignment (or the arrival of a new patient) is independent of
the time to toxicity.
Under the missing data mechanism (2.2), the induced missing data are
nonignorable or informative because the probability of missingness of Yi
depends on the underlying time to toxicity, and thus implicitly depends on
the value of Yi itself. More specifically, the data from patients who would
not experience toxicity (Yi = 0) in the assessment period are more likely to
be missing than data from patients who would experience toxicity (Yi = 1).
The next theorem provides a new insight to the issue of late-onset toxicity.
Theorem 1. Under the missing data mechanism (2.2), the missing data
induced by late-onset toxicity are nonignorable with Pr(Mi = 1|Yi = 0) >
Pr(Mi = 1|Yi = 1).
The proof of the theorem is briefly sketched in the Appendix. In general,
the missing data are more likely to occur for those patients who would
not experience toxicity in (0, T ). This phenomenon is also illustrated in
Figure 1. Patient 2 who will not experience toxicity during the assessment
period is more likely to have a missing toxicity outcome at the decision-
making times 2τ and 3τ than patient 1 who has experienced toxicity between
times τ and 2τ . Compared with other missing data mechanisms, such as
missing completely at random or missing at random, nonignorable missing
data are the most difficult to deal with [Little and Rubin (2002)], which
brings a new challenge to clinical trial designs. Because the missing data are
nonignorable, the naive approach by simply discarding the missing data and
making dose-escalation decisions solely based on the observed toxicity data
is problematic. The observed data represent a biased sample of the complete
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data and contain more toxicity observations than they should be because
the responses for patients who would experience toxicity are more likely to
be observed. As a result, approaches based only on the observed toxicity
data typically overestimate the toxicity probabilities and thus lead to overly
conservative dose escalation.
During the trial conduct, the amount of missing data depends on the ratio
of the assessment period T and the interarrival time τ , denoted as the A/I
ratio = T/τ . The larger the value of the A/I ratio, the greater the amount of
missing data that would be produced, because there would be more patients
who may not have completed the toxicity assessment when a new cohort
arrives.
2.3. DA-CRM using Bayesian data augmentation. An intuitive approach
to dealing with the unobserved toxicity outcomes is to impute the missing
data so that the standard complete-data method can be applied. One way
to achieve this goal is to use data augmentation (DA) proposed by Tanner
and Wong (1987). The DA iterates between two steps: the imputation (I)
step, in which the missing data are imputed, and the posterior (P) step,
in which the posterior samples of unknown parameters are simulated based
on the imputed data. As the CRM is originally formulated in the Bayesian
framework [O’Quigley, Pepe and Fisher (1990)], the DA provides a natu-
ral and coherent way to address the missing data issue due to late-onset
toxicity. Note that the missing data we consider here is a special case of
nonignorable missing data with a known missing data mechanism as defined
by (2.2). Therefore, the nonidentification problem that often plagues the
nonignorable missing data can be circumvented as follows.
In order to obtain consistent estimates, we need to model the nonignorable
missing data mechanism in (2.2). Toward this goal, we specify a flexible
piecewise exponential model for the time to toxicity for patients who would
experience DLTs, which concerns the conditional distribution of ti given Yi =
1. Specifically, we consider a partition of the follow-up period [0, T ] into K
disjoint intervals [0, h1), [h1, h2), . . . , [hK−1, hK ≡ T ], and assume a constant
hazard λk in the kth interval. Define the observed time xi =min(ui, ti) and
δik = 1 if the ith subject experiences toxicity in the kth interval; and δik = 0
otherwise. Let λ = {λ1, . . . , λK}; when the toxicity data y = {y1, . . . , yn}
are completely observed, the likelihood function of λ based on n enrolled
subjects is given by
L(y|λ) =
n∏
i=1
K∏
k=1
λδikk exp{−yiλksik},
where sik = hk − hk−1 if xi > hk; sik = xi − hk−1 if xi ∈ [hk−1, hk); and oth-
erwise sik = 0. Similar to the TITE-CRM, we assume that the time-to-DLT
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distribution is invariant to the dose level, conditioning on that the patient
will experience toxicity (Yi = 1). This assumption is helpful to pool informa-
tion across different doses and obtain more reliable estimates. The sensitivity
analysis in Section 3.2 shows that our method is not sensitive to the violation
of this assumption.
In the Bayesian paradigm, we assign each component of λ an independent
gamma prior distribution with the shape parameter ζk and the rate param-
eter ξk, denoted as Ga(ζk, ξk). When there is some prior knowledge available
regarding the shape of the hazard for the time to toxicity, the hyperparam-
eters ζk and ξk can be calibrated to match the prior information. Here we
focus on the common case in which the prior information is vague and we
aim to develop a default and automatic prior distribution for general use.
Specifically, we assume that a priori toxicity occurs uniformly throughout
the assessment period (0, T ), which represents a neutral prior opinion be-
tween early-onset and late-onset toxicity. Under this assumption, the hazard
at the middle of the kth partition is λ˜k =K/{T (K − k + 0.5)}. Thus, we
assign λk a gamma prior distribution,
λk =Ga(λ˜k/C,1/C),
where C is a constant determining the size of the variance with respect to
the mean, as the mean for this prior distribution is λ˜k and the variance is
Cλ˜k. Based on our simulations, we found that C = 2 yields a reasonably
vague prior and equips the design with good operating characteristics.
Based on the time-to-toxicity model as above, the DA algorithm can be
implemented as follows. At the I step of the DA, we “impute” the missing
data by drawing posterior samples from their full conditional distributions.
Let y = (yobs,ymis), where yobs and ymis denote the observed and missing
toxicity data, respectively; and let Dobs = (yobs,M) denote the observed
data with missing indicators M = {Mi, i = 1, . . . , n}. As the missing data
are informative, the observed data used for inference include not only the
observed toxicity outcomes yobs, but also the missing data indicators M.
Inference that ignores M (such as the CRM) would lead to biased estimates.
It can be shown that, conditional on the observed data Dobs and model
parameters (a,λ), the full conditional distribution of yi ∈ ymis is given by
yi|(Dobs, a,λ)∼ Bernoulli
(
α
exp(a)
di
exp(−
∑K
k=1 λksik)
1− α
exp(a)
di
+ α
exp(a)
di
exp(−
∑K
k=1λksik)
)
.
At the P step of the DA, given the imputed data y, we sequentially sample
the unknown model parameters from their full conditional distributions as
follows:
(i) Sample a from f(a|y) given by (2.1), where y is the “complete” data
after filling in the missing outcomes.
BAYESIAN DATA AUGMENTATION DOSE FINDING 9
(ii) Sample λk, k = 1, . . . ,K, from
λk|y∼Ga
(
λ˜k/C +
n∑
i=1
δik,1/C +
n∑
i=1
yisik
)
.
The DA procedure iteratively draws a sequence of samples of the missing
data and model parameters through the imputation (I) step and posterior
(P) step until the Markov chain converges. The posterior samples of a can
then be used to make inference on pid to direct dose finding.
2.4. Dose-finding algorithm. Let φ denote the physician-specified toxic-
ity target, and assume that patients are treated in cohorts, for example, with
a cohort size of three. For safety, we restrict dose escalation or de-escalation
by one dose level of change at a time. The dose-finding algorithm for the
DA-CRM is described as follows:
(1) Patients in the first cohort are treated at the lowest dose level.
(2) At the current dose level dcurr, based on the cumulated data, we obtain
the posterior means for the toxicity probabilities, pˆid (d= 1, . . . , J). We then
find dose level d∗ that has a toxicity probability closest to φ, that is,
d∗ = argmin
d∈(1,...,J)
|pˆid − φ|.
• If dcurr > d∗, we de-escalate the dose level to dcurr − 1;
• if dcurr < d∗, we escalate the dose level to dcurr +1;
• otherwise, the dose stays at the same level as dcurr for the next cohort of
patients.
(3) Once the maximum sample size is reached, the dose that has the
toxicity probability closest to φ is selected as the MTD.
In addition, we also impose an early stopping rule for safety: if Pr(pi1 >
φ|Dobs) > 0.96, the trial will be terminated. That is, if the lowest dose is
still overly toxic, the trial should be stopped early.
3. Numerical studies.
3.1. Simulations. To examine the operating characteristics of the DA-
CRM design, we conducted extensive simulation studies. We considered six
dose levels and assumed that toxicity monotonically increased with respect
to the dose. The target toxicity probability was 30% and a maximum num-
ber of 12 cohorts were treated sequentially in a cohort size of three. The
sample size was chosen to match the maximum sample size required by
the conventional “3 + 3” design. The toxicity assessment period was T = 3
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months and the accrual rate was 6 patients per month. That is, the inter-
arrival time between every two consecutive cohorts was τ = 0.5 month with
the A/I ratio = 6.
We considered four toxicity scenarios in which the MTD was located at
different dose levels. Due to the limitation of space, we show only scenarios
1 and 2 in Table 1, and the other scenarios are provided in Table S1 of
the supplementary materials [Liu, Yin and Yuan (2013)]. Under each sce-
nario, we simulated times to toxicity based on Weibull, log-logistic and uni-
form distributions, respectively. For Weibull and log-logistic distributions,
we controlled that 70% toxicity events would occur in the latter half of the
assessment period (T/2, T ). Specifically, at each dose level, the scale and
shape parameters of the Weibull distribution were chosen such that
(1) the cumulative distribution function at the end of the follow-up time
T would be the toxicity probability of that dose; and
(2) among all the toxicities that occurred in (0, T ), 70% of them would
occur in (T/2, T ), the latter half of the assessment period.
Because the toxicity probability varies across different dose levels, the scale
and shape parameters of the Weibull distribution need to be carefully chosen
for different dose levels, and similarly for the scale and location parameters
of the log-logistic distribution. For the uniform distribution, we simulated
the time to toxicity independently for each dose level and controlled the
cumulative distribution function at the end of the follow-up time T match-
ing the toxicity probability of each dose. In the proposed DA-CRM, we
usedK = 9 partitions to construct the piecewise exponential time-to-toxicity
model. We compared the DA-CRM with the CRMobs, which determined the
dose assignment based on only the observed toxicity data as suggested by
O’Quigley, Pepe and Fisher (1990), and the TITE-CRM with the adaptive
weighting scheme proposed by Cheung and Chappell (2000). As a bench-
mark for comparison, we also implemented the complete-data version of the
CRM (denoted by CRMcomp), assuming that all of the toxicity outcomes
in the trial were completely observed prior to each dose assignment. The
CRMcomp required repeatedly suspending the accrual prior to each dose
assignment to wait that all of the toxicity outcomes in the trial were com-
pletely observed. Although the CRMcomp is not feasible in practice when
toxicities are late-onset, it provides an optimal upper bound to evaluate the
performances of other designs. Actually, when all toxicity outcomes are ob-
servable (i.e., no missing data), the DA-CRM and TITE-CRM are equivalent
to the complete-data CRMcomp. For all methods, we set the probability con-
stants in the CRM (α1, . . . , α6) = (0.08,0.12,0.20,0.30,0.40, 0.50) and used
a normal prior distribution N(0,2) for parameter a. Under each scenario,
we simulated 5000 trials.
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Table 1
Simulation study comparing the complete-data CRM (CRMcomp), the CRM based on the
observed toxicity data only (CRMobs), time-to-event CRM (TITE-CRM) and the
proposed data augmentation CRM (DA-CRM) with the sample size 36, the cohort size 3
and the A/I ratio = 6
Recommendation percentage at dose level
Time to
toxicity Design 1 2 3 4 5 6 None NMTD+
Duration
(months)
Scenario 1 Pr(toxicity) 0.1 0.15 0.3 0.45 0.6 0.7
CRMcomp 0.6 13.8 61.9 22.9 0.6 0.0 0.2 9.0 36.4
# patients 4.8 7.2 14.9 7.6 1.3 0.1
Weibull CRMobs 0.4 7.5 48.4 27.4 2.4 0.1 13.7 4.0 8.2
# patients 7.5 8.3 13.2 3.0 0.9 0.1
TITE-CRM 3.4 23.1 55.9 16.5 0.6 0.0 0.5 15.5 9.0
# patients 5.1 6.3 9.0 8.1 4.9 2.5
DA-CRM 0.9 14.7 56.4 25.1 1.5 0.0 1.2 10.4 8.9
# patients 9.4 7.6 8.3 6.0 3.0 1.3
Log-logistic CRMobs 0.3 7.8 48.2 27.4 2.7 0.1 13.6 4.0 8.2
# patients 7.4 8.4 13.2 3.0 0.9 0.1
TITE-CRM 3.6 22.6 56.3 16.5 0.6 0.0 0.4 15.4 9.0
# patients 5.1 6.4 9.1 8.2 4.8 2.4
DA-CRM 0.9 13.9 58.1 23.8 1.9 0.0 1.3 10.3 8.9
# patients 9.5 7.6 8.2 6.0 3.0 1.3
Uniform CRMobs 0.1 4.7 38.0 30.5 2.9 0.1 23.6 2.8 7.5
# patients 8.6 8.2 10.9 2.3 0.5 0.0
TITE-CRM 2.1 20.4 56.6 19.1 1.4 0.0 0.4 13.0 9.0
# patients 6.3 7.0 9.7 8.0 3.7 1.3
DA-CRM 0.6 11.2 56.9 27.6 1.7 0.0 1.9 8.7 8.9
# patients 10.8 7.6 8.5 5.7 2.2 0.7
Scenario 2 Pr(toxicity) 0.08 0.1 0.2 0.3 0.45 0.6
CRMcomp 0.0 1.4 23 55.9 18.8 0.8 0.1 6.6 36.4
# patients 4.1 4.1 9.0 12.2 5.5 1.0
Weibull CRMobs 0.0 1.0 18.9 48.5 22.2 1.8 7.6 2.9 8.5
# patients 5.7 6.7 13.8 5.2 2.3 0.7
TITE-CRM 0.1 2.6 29.2 52.4 14.9 0.8 0.1 11.2 9.0
# patients 4.2 4.7 7.1 8.8 6.8 4.4
DA-CRM 0.0 1.5 24.4 54.0 17.7 1.4 1.1 7.3 8.9
# patients 8.4 6.3 7.0 6.7 4.5 2.8
Log-logistic CRMobs 0.0 0.9 19.0 48.5 22.0 1.9 7.7 2.9 8.5
# patients 5.7 6.7 13.8 5.1 2.3 0.7
TITE-CRM 0.1 2.6 29.0 52.3 15.1 0.8 0.1 11.1 9.0
# patients 4.1 4.7 7.2 8.8 6.8 4.3
DA-CRM 0.0 1.4 23.3 54.0 18.7 1.6 1.0 7.5 8.9
# patients 8.3 6.2 6.9 6.8 4.6 2.9
Uniform CRMobs 0.0 0.7 14.9 45.3 23.3 2.3 13.5 2.0 8.1
# patients 6.9 7.1 12.3 4.5 1.7 0.4
TITE-CRM 0.1 2.2 26.9 54.4 15.4 0.9 0.1 9.6 9.0
# patients 4.9 5.0 7.6 8.8 6.2 3.3
DA-CRM 0.0 1.3 23.7 54.0 18.8 1.1 1.2 6.2 8.9
# patients 9.3 6.3 7.1 6.8 4.2 2.0
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Following each scenario in Tables 1 and S1, the first row is the true tox-
icity probabilities; rows 2 and 3 show the dose selection probability (with
the percentage of inconclusive trials denoted by “None”) and the average
number of patients treated at each dose based on the complete-data de-
sign CRMcomp, respectively; the remaining rows provide the corresponding
summary statistics for the CRMobs, TITE-CRM and DA-CRM under var-
ious settings of late-onset toxicity and time-to-toxicity distributions. The
CRMcomp does not depend on the distributions of the times to toxicity be-
cause the design assumes that all toxicity outcomes are completely observed
before each dose assignment.
When evaluating the trial designs with late-onset toxicities, one of the
most important measures of the design performance is patient safety because
the main issue of the late-onset toxicities is that ignoring them will lead
to overly aggressive dose escalation and thus treating too many patients
at excessively toxic doses, that is, the doses higher than the MTD. As a
measure of safety, in Tables 1 and S1, we also report the number of patients
treated at doses above the MTD (denoted as NMTD+) averaged across 5000
simulated trials.
In scenario 1, the MTD (shown in boldface) is at dose level 3, and the
complete-data design CRMcomp yielded an optimal selection probability of
61.9%. The selection probability of the MTD using the DA-CRM was slightly
lower than this optimal value, but higher than that of using the CRMobs.
For instance, when the time to toxicity followed the log-logistic distribution,
the selection probability using the DA-CRM was 58.1%, whereas that of the
CRMobs was 48.2%. The CRMobs appeared to be overly conservative and led
to a high percentage (about 13.6%) of inconclusive trials. This was because
the CRMobs estimated the toxicity probabilities based solely on the observed
toxicity data, which is a biased sample of the complete data with an excessive
number of toxicities. Therefore, the CRMobs tended to overestimate the
toxicity probabilities, resulting in conservative dose escalations and high
percentages of early termination of the trial. The TITE-CRM yielded similar
selection percentages as the DA-CRM, but the DA-CRM was much safer:
the number of patients treated above the MTD (i.e., NMTD+) using the DA-
CRM was notably smaller than that of the TITE-CRM and close to that of
the complete-data design. For example, when the time to toxicity followed
the Weibull distribution, NMTD+ was 9.0 and 10.4 using the complete-data
design and the DA-CRM, respectively, while that based on the TITE-CRM
was 15.5. As the CRMobs is overly conservative, NMTD+ = 4.0 is the smallest
under the CRMobs.
In scenario 2, the MTD is the fourth dose, and in scenario 3 (see Table
S1), the MTD is the second. Compared to the TITE-CRM, the DA-CRM
yielded comparable MTD-selection probabilities but appeared to be safer,
which reduced NMTD+ by more than 30% in both scenarios. For example,
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in scenario 2, when the time to toxicity followed the Weibull distribution,
NMTD+ using the DA-CRM was 7.3, approximately 35% less than that using
the TITE-CRM (NMTD+ = 11.2). A similar extent of decreasing in NMTD+
was observed in scenario 3 when using the DA-CRM. The CRMobs again led
to a high percentage of inconclusive trials (particularly under the uniform
distribution) and a relatively low selection percentage of the MTD due to
the overestimation of the toxicity probabilities. For scenario 4 in Table S1,
in which the fifth dose is the MTD, the CRMobs yielded a similar selection
percentage as the TITE-CRM and DA-CRM.
We further investigated the performance of the designs under a smaller
sample size of 27 patients treated in a cohort size of 3, and 21 patients
treated in a cohort size of 1. The pattern of the results is generally similar to
those described above (see Tables S2 and S3 in the supplementary materials
[Liu, Yin and Yuan (2013)]). We also examined the operating characteristics
of the DA-CRM under a lower A/I ratio of 3 with the cohort interarrival
time τ = 1 month (see Table S4 in the supplementary materials [Liu, Yin
and Yuan (2013)]). In this case, the accrual rate was relatively slower and,
thus, late-onset toxicities became of less concern since the majority of tox-
icity outcomes would be observed at the moment of dose assignment. As
expected, the performances of the CRMobs, TITE-CRM and DA-CRM were
rather comparable across different scenarios and time-toxicity distributions.
Actually, when the A/I ratio is less than or equal to 1 (i.e., no late-onset
toxicities and no missing data), the CRMobs, TITE-CRM and DA-CRM are
exactly the same.
These results suggest that, when the A/I ratio is low (e.g., when the
disease under study is rare and thus the accrual rate is slow), the CRMobs has
little bias and is still a good design option for phase I clinical trials. However,
when the accrual is fast, for example, in multi-center clinical trials for some
common type of cancer (e.g., breast or lung cancer), the A/I ratio can be high
(particularly when radiotherapies or some targeted agents are used), and
using the proposed DA-CRM can lead to better operating characteristics.
3.2. Sensitivity analysis. We investigated the robustness of the proposed
DA-CRM design when (1) the underlying times to toxicity were heteroge-
neous across the doses, by simulating the times to toxicity from a Weibull
distribution at dose levels of 1, 3 and 5, and from a log-logistic distribu-
tion at dose levels of 2, 4 and 6; (2) the number of partitions used in the
piecewise exponential model for the times to toxicity was K = 5 and 12; and
(3) the prior distribution for a was N(0,0.57), the “least-informative” prior
proposed by Lee and Cheung (2011). The results show that the performance
of the DA-CRM (e.g., the selection percentages and NMTD+) was very sim-
ilar across different conditions (see Table S5 in the supplementary materials
[Liu, Yin and Yuan (2013)]), which suggests the robustness of the proposed
design.
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Table 2
Days, doses and DLTs for eighteen evaluable patients enrolled in the pancreatic cancer
trial
Patient Day on Day off Dose Patient Day on Day off Dose
No. study∗ study∗ (mg/m2) DLT No. study∗ study∗ (mg/m2) DLT
1 0 67 30 No 10 224 291 50 No
2 43 98 30 No 11 280 303 50 Yes
3 50 116 30 No 12 301 347 50 Yes
4 56 108 30 No 13 322 382 50 No
5 70 133 40 No 14 329 389 50 No
6 147 217 40 No 15 343 372 50 Yes
7 161 224 40 No 16 364 423 40 No
8 182 238 40 No 17 371 408 50 Yes
9 224 284 50 No 18 455 528 30 No
* days since the initiation of the study.
4. Applications.
4.1. Pancreatic cancer trial. Muler et al. (2004) described a phase I trial
to determine the MTD of cisplatin that could be added to the full-dose
gemcitabine and radiation therapy in patients with pancreatic cancer. The
protocol treatment consisted of two 28-day cycles of chemotherapy, with
radiation given during the first cycle of chemotherapy. Radiation and gem-
citabine doses were held constant, while four dose levels of cisplatin (20, 30,
40 and 50 mg/m2) were investigated in the trial. The DLTs were defined as
CTCAE 2.0 grade 4 thrombocytopenia, grade 4 neutropenia lasting more
than 7 days or grade 3 toxicity in other organ systems. Patients were required
to be followed for nine weeks in order to fully assess their toxicity outcomes.
The goal of the trial was to determine the dose of cisplatin associated with
a target DLT rate of 20%.
As shown in Table 2, one challenge of designing this trial is that the
accrual was fast, compared to the 9-week assessment period for DLTs (i.e.,
the toxicity was late-onset). In the DA-CRM design, we took α= (0.1,0.15,
0.2,0.25) as the prior estimates of the toxicity probabilities for the four dose
levels of cisplatin, and used 30 mg/m2 as the starting dose of the trial.
For patient safety, we required that at least two patients must have fully
completed their toxicity assessment at the lower dose before the dose can be
escalated to the next higher level.
Figure 2 summarizes how the posterior estimates of the toxicity proba-
bilities of four doses were updated as more patients were enrolled during
the trial conduct. The first four patients were assigned to the dose of 30
mg/m2. Based on the days from the initiation of the trial, when patient 5
arrived on day 70, patient 1 had completed the follow-up, while patients 2,
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Fig. 2. Estimates of the toxicity probabilities of four doses with the cumulative number
of patients in the pancreatic cancer trial. Numbers 1–4 in the figure indicate the four dose
levels.
3 and 4 had finished only 43%, 32% and 22% of their follow-ups, without
experiencing any DLTs. The estimates of toxicity probabilities of four doses
were pˆi = (0.113,0.131,0.148,0.165). We escalated the dose and subsequently
treated patients 5 to 8 at the dose of 40 mg/m2. Patient 2 died after 63 days
on therapy, but was judged to be secondary to the hypercoaguable state
associated with pancreatic cancer. Therefore, that death was classified as
unrelated to therapy (i.e., not a DLT).
Upon the arrival of patient 9 on day 224, patients 1 to 7 had completed
their toxicity assessment and none of them had experienced DLT. These
data yielded the updated toxicity estimates pˆi = (0.005,0.008,0.013,0.019),
suggesting that the doses of 30 mg/m2 and 40 mg/m2 were safe. As a result,
we further escalated the dose and assigned patients 9 to 11 to 50 mg/m2.
On day 301 when patient 12 was accrued, patients 1 to 10 had completed
their toxicity assessment without experiencing DLT, yielding the updated
estimates of the toxicity probabilities pˆi = (0.007,0.012,0.019,0.027). Conse-
quently, patients 12 to 15 were also treated at 50 mg/m2.
After patient 12 experienced a DLT (i.e., duodenal ulcer) on day 347,
the estimates of the toxicity probabilities began to increase, that is, pˆi =
(0.085,0.125,0.165,0.207), but not sufficiently to trigger dose de-escalation.
According to the dose-finding algorithm, the incoming patients 16 and 17
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should be treated at 50 mg/m2. However, because the investigators were
concerned about a potential DLT in patient 15, only patient 17 was treated
at 50 mg/m2, while patient 16 was treated at a lower dose 40 mg/m2.
By the time that patient 18, the last enrolled patient, arrived on day 455, 4
out of 8 patients previously treated at 50 mg/m2 had experienced DLTs (i.e.,
one duodenal ulcer, one diarrhea resulting in dehydration, and two grade 3
anorexia and nausea leading to a two-level decline in performance status).
This significantly increased pˆi to (0.126, 0.177, 0.228, 0.275). Therefore, pa-
tient 18 was assigned to a lower dose 30 mg/m2. At the end of the trial, the
estimates of the toxicity probabilities were pˆi = (0.118,0.167,0.215,0.264)
and, thus, the dose 40 mg/m2 was selected as the MTD because its esti-
mated toxicity probability was closest to the target of 0.2.
4.2. Esophageal cancer trial. In the esophageal cancer clinical trial de-
scribed in Introduction, the target toxicity probability was 30% and a total
of 30 patients were treated sequentially in cohorts of size 3. Six doses were
investigated and the trial started by treating the first cohort at dose level
1. Under the DA-CRM design, the posterior estimates of the dose–toxicity
probabilities were updated only when the first patient of each new cohort
(i.e., patient 4, 7, 10, 13, 16, . . . ) was enrolled.
The three patients in cohort 1 were enrolled at days 3, 6 and 18, respec-
tively (see Table S6 in the supplementary materials [Liu, Yin and Yuan
(2013)]). On day 28 when patient 4 (i.e., the first patient of cohort 2)
was enrolled, the three patients in cohort 1 had finished only 28%, 24%
and 11% of their 3-month follow-ups without experiencing toxicity (i.e.,
DLT). The estimates of the toxicity probabilities of six dose levels were pˆi =
(0.172,0.185,0.209,0.236,0.264,0.294). We escalated the dose and treated
patient 4, and subsequently patients 5 and 6, at dose level 2.
When patient 7 (the first patient of cohort 3) arrived on day 57, we
again updated the estimates of the toxicity probabilities and obtained pˆi =
(0.315,0.336,0.369,0.407,0.445,0.486). Although at that moment we still
had not observed any DLTs yet, the values of pˆi increased compared with
the previous estimates of pi. This is because on day 57, more patients (i.e.,
patients 1 to 6) were under treatment and none of them had finished their
3-month follow-ups yet. There was greater uncertainty regarding the toxicity
probabilities of the doses and it was preferable to be conservative. Our al-
gorithm automatically took into account such uncertainty and de-escalated
the dose back to the first level for treating cohort 3.
On day 91 when the first patient of cohort 4 (i.e., patient 10) was accrued,
patients 1, 2 and 3 were very close to completing their 3-month follow-ups
without experiencing toxicity, indicating that the first dose level was safe
and dose escalation was needed. The proposed algorithm timely reflected
this data information and escalated the dose to level 2. The dose was further
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Fig. 3. Estimate of the unknown parameter a with cumulative cohorts in the esophageal
cancer trial.
escalated to levels 3 and 4 for treating cohorts 5 and 6, respectively, as no
DLT was observed. By the time patient 19 arrived, the toxicity outcomes of
all patients treated in the trial had been observed. In particular, all three
patients (i.e., patients 16–18) treated at dose level 4 had experienced DLTs.
Our algorithm de-escalated the dose to level 3 to treat cohort 7. Thereafter,
there were always at least 18 toxicity outcomes (from patients 1–18) fully
observed, thus, pˆi became rather stable and consistently indicated that dose
3 was the MTD. The last 3 cohorts were all treated at dose level 3 and, at
the end of the trial, dose 3 was selected as the MTD with the estimated
toxicity probability of 0.259.
Figure 3 displays the estimate of the unknown parameter a during the
trial conduct. At the beginning of the trial, there was much variability for the
estimate of a due to sparse data, while the estimate became stabilized after
six cohorts of patients were enrolled. Correspondingly, Table 3 summarizes
the estimates of the toxicity probabilities pi for the six doses at each decision-
making time.
5. Conclusions. We have proposed the DA-CRM design to address the
issues associated with late-onset toxicities in phase I dose-finding trials. In
the new design, unobserved toxicity outcomes are naturally treated as miss-
ing data. We established that such missing data are nonignorable and linked
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Table 3
Estimates of the toxicity probabilities of six doses with the cumulative number of cohorts
in the esophageal cancer trial
Cumulative number of cohorts
Dose level 1 2 3 4 5 6 7 8 9 10
1 0.172 0.315 0.028 0.021 0.080 0.175 0.186 0.171 0.189 0.125
2 0.185 0.336 0.035 0.026 0.114 0.228 0.240 0.223 0.243 0.172
3 0.209 0.369 0.050 0.037 0.181 0.320 0.333 0.314 0.337 0.259
4 0.236 0.407 0.071 0.053 0.268 0.422 0.435 0.415 0.440 0.361
5 0.264 0.445 0.096 0.071 0.359 0.515 0.528 0.509 0.532 0.458
6 0.294 0.486 0.128 0.093 0.454 0.603 0.615 0.598 0.619 0.553
the missing data mechanism with the time to toxicity based on a flexible
piecewise exponential model. Simulation studies showed that the DA-CRM
outperforms other available methods, particularly when toxicities need a
long follow-up time to be assessed. The selection percentage of the DA-
CRM is often close to the optimal value, and many fewer patients would be
treated at overly toxic doses.
This paper has focused on the single-agent dose finding using the CRM,
but the proposed methodology provides a general and systematic approach
to transforming the late-onset toxicity problem into a standard complete-
data problem by imputing the missing toxicity outcomes. The proposed
method can serve as a universal adaptor to extend existing trial designs
to accommodate more complicated dose-finding problems with late-onset
toxicity. For example, by incorporating the data augmentation procedure
into the partial-order CRM [Wages, Conaway and O’Quigley (2011)], we
can address the late-onset toxicity for drug-combination trials or dose finding
with group heterogeneity. It is also worth emphasizing that although we have
focused on the late-onset toxicity, the proposed method can also be used to
handle other kinds of late-onset outcomes, such as delayed efficacy responses
in phase I/II or phase II trials, as well as response-adaptive randomization
designs.
APPENDIX: PROOF OF THEOREM 1
Considering that each subject is fully followed up to T , if ti > T , then
Yi = 0; and if ti ≤ T , then Yi = 1. We demonstrate the nonignorable miss-
ingness for the missing data caused by late-onset toxicity as follows. For a
subject who will not experience toxicity, the probability that his/her toxicity
outcome will be missing is given by
Pr(Mi = 1|Yi = 0) = Pr(ti > ui, ui < T |Yi = 0)
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=Pr(ui < T |Yi = 0)Pr(ti >ui|ui < T,Yi = 0)
= Pr(ui < T |ti > T )Pr(ti > ui|ui < T, ti >T )
= Pr(ui < T ),
where the last equality follows because ti and ui are independent, and Pr(ti >
ui|ui < T, ti > T ) = 1. Similarly, for a subject who will experience toxicity,
the probability that his/her toxicity outcome will be missing is given by
Pr(Mi = 1|Yi = 1) = Pr(ti > ui, ui < T |Yi = 1)
= Pr(ui < T |Yi = 1)Pr(ti >ui|ui < T,Yi = 1)
= Pr(ui < T |ti ≤ T )Pr(ti > ui|ui < T, ti ≤ T )
= Pr(ui < T )Pr(ti >ui|ui < T, ti ≤ T ).
Because of Pr(ti > ui|ui < T, ti ≤ T )< 1, it follows that
Pr(Mi = 1|Yi = 0)>Pr(Mi = 1|Yi = 1).
Therefore, the missing data are more likely to occur for those patients who
will not experience toxicity in (0, T ).
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